DEA Regulations and Research Impact

In this episode, Joe interviews renowned chemist, filmmaker, and journalist, Hamilton Morris. 

After originally backing down from its first attempt in 2022, the DEA is once again looking to apply schedule I status to two lesser-known compounds: DOI (2,5-dimethoxy-4-iodoamphetamine) and DOC (2,5-dimethoxy-4-chloroamphetamine). For decades, DOI and DOC have been incredible tools for researchers studying serotonin receptors, showing promise for chronic pain, anxiety, depression, and more.

Originally recorded as a livestream in November, we felt this discussion deserved more attention, as Morris was present during the hearing and saw first-hand the damage that can come from the combination of immense overreach and outdated beliefs.

He talks about:

• The bureaucratic mess behind so much of what the DEA doe
• The safety profile and research capacity of DOI and DOC and complete lack of data showing recreational us
• The DEA’s claim that advocates weren’t expert
• The fight to protect the Sonoran Desert toad and more!

While we wait for the conclusion of the hearing, head to Hamilton’s Patreon to hear his daily breakdowns. For links, head to the show notes page.